JP2021529792A5 - - Google Patents

Info

Publication number
JP2021529792A5
JP2021529792A5 JP2020573524A JP2020573524A JP2021529792A5 JP 2021529792 A5 JP2021529792 A5 JP 2021529792A5 JP 2020573524 A JP2020573524 A JP 2020573524A JP 2020573524 A JP2020573524 A JP 2020573524A JP 2021529792 A5 JP2021529792 A5 JP 2021529792A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
hydrogen
clathrate
prodrug
Prior art date
Application number
JP2020573524A
Other languages
English (en)
Japanese (ja)
Other versions
JP7561632B2 (ja
JP2021529792A (ja
JPWO2020006296A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039600 external-priority patent/WO2020006296A1/en
Publication of JP2021529792A publication Critical patent/JP2021529792A/ja
Publication of JP2021529792A5 publication Critical patent/JP2021529792A5/ja
Publication of JPWO2020006296A5 publication Critical patent/JPWO2020006296A5/ja
Priority to JP2024094936A priority Critical patent/JP2024138260A/ja
Application granted granted Critical
Publication of JP7561632B2 publication Critical patent/JP7561632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573524A 2018-06-27 2019-06-27 プロテアソーム活性増強化合物 Active JP7561632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094936A JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690563P 2018-06-27 2018-06-27
US201862690565P 2018-06-27 2018-06-27
US62/690,565 2018-06-27
US62/690,563 2018-06-27
PCT/US2019/039600 WO2020006296A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094936A Division JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Publications (4)

Publication Number Publication Date
JP2021529792A JP2021529792A (ja) 2021-11-04
JP2021529792A5 true JP2021529792A5 (https=) 2022-06-29
JPWO2020006296A5 JPWO2020006296A5 (https=) 2022-06-29
JP7561632B2 JP7561632B2 (ja) 2024-10-04

Family

ID=67439356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573524A Active JP7561632B2 (ja) 2018-06-27 2019-06-27 プロテアソーム活性増強化合物
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Country Status (17)

Country Link
US (2) US11560385B2 (https=)
EP (1) EP3814338A1 (https=)
JP (2) JP7561632B2 (https=)
KR (1) KR20210024588A (https=)
CN (1) CN112585132B (https=)
AU (1) AU2019295765B2 (https=)
BR (2) BR112020026580A2 (https=)
CA (1) CA3103954A1 (https=)
CL (1) CL2020003380A1 (https=)
CR (1) CR20200652A (https=)
IL (1) IL279698A (https=)
MA (1) MA53014A (https=)
MX (1) MX2020014082A (https=)
PE (1) PE20211804A1 (https=)
PH (1) PH12020552261A1 (https=)
SG (1) SG11202013026WA (https=)
WO (1) WO2020006296A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
CN112142642B (zh) * 2020-10-15 2022-03-04 华侨大学 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法
WO2023107597A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroaromatic amide compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154744A (en) 1966-05-17 1969-06-11 Whitefin Holding Sa Disubstituted Aminoethanols
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
CZ20002669A3 (cs) 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
EP1682504B1 (en) 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxy piperidine derivatives to treat gaucher disease
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101541172A (zh) 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
JP5303458B2 (ja) 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
MX336731B (es) * 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
DK2707101T3 (da) * 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Similar Documents

Publication Publication Date Title
JP2021529792A5 (https=)
JP2016531121A5 (https=)
JP2017132814A5 (https=)
JP2019514874A5 (https=)
JP2015522650A5 (https=)
JP2015527387A5 (https=)
AR082218A1 (es) Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion
JP2017506666A5 (https=)
RU2016125306A (ru) Новые пестицидные соединения и применения
JP2017503833A5 (https=)
JP2009511490A5 (https=)
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
JP2010535722A5 (https=)
JP2016505614A5 (https=)
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
RU2016118399A (ru) Производные 4-аминометилбензойной кислоты
JP2016531126A5 (https=)
JP2019529419A5 (https=)
MX395406B (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
JP2015535847A5 (https=)
JP2016503778A5 (https=)
JP2006508979A5 (https=)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
RU2314292C2 (ru) Производные азетидина в качестве антагонистов ccr-3 рецептора
RU2007147597A (ru) Производные эрголина и их применение в качестве лигандов хемокинного рецептора